- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
Long-acting injectable PrEP is an experimental strategy based on the drug cabotegravir, an antiviral medication.
Two studies, HPTN 083 and HPTN 084, have shown high levels of protection using cabotegravir as a long acting injectable (CAB-LA). HPTN 083 gathered data among men who have sex with men, transgender women. HPTN 084 investigated the same product among cisgender women.
In December of 2021, the FDA approved CAB-LA as PrEP, making it the first injectable PrEP to be added to the toolbox of proven prevention methods, along with male and female condoms, daily oral PrEP, voluntary medical male circumcision and the Dapivirine Vaginal Ring.
Scroll down for resources on CAB-LA research and advocacy.
Next Steps for Access for CAB for PrEP
- The Coalition to Accelerate Access to Long-Acting PrEP—This initiative includes donors, agencies, and advocates working in four areas: Needs and Demand Assessment, New Product Access Pathway, Financing & Procurement, and Demand creation & Policy Adoption. The aim is an accelerated, equitable, sustainable and collaborative approach to making longer-acting PrEP options accessible as quickly and as equitably as possible. The Coalition is convened by Unitaid, WHO, UNAIDS, The Global Fund, and PEPFAR with AVAC as the Secretariat.
- A collaboration within the coalition, under its working group on access, is focused on expediting access to injectable CAB for PrEP in the near term in resource-limited settings.
- ViiV’s 2022-2024 strategy for community stakeholder engagement in low and middle income countries pledges a commitment to Good Participatory Practice Guidelines and more. See the full strategy here.
AVAC’s Plan for Accelerating Access and Introduction of Injectable CAB for PrEP
- AVAC’s Plan for Accelerating Access and Introduction of Injectable CAB for PrEP provides a comprehensive view of all the moving parts involved in delivering this new PrEP option and identifies priorities for ensuring time is not wasted and opportunity is not squandered.
- Summary document also available.
Updates
Understanding the Research Results
- An Advocates’ Primer on Injectable Cabotegravir for PrEP: Trials, Approvals, Rollout and More, AVAC, February 2022
- CAB-LA is a Highly Effective HIV Prevention Option; Now what? (23:06), AVAC podcast, December 2020
- Landmark Trial in East and Southern Africa Finds Injectable PrEP Safe and Effective for Cisgender Women, AVAC, November 2020
- Resource page on HPTN 084 trial design and results, HPTN, November 2020
- HPTN 084 FAQ, HPTN, November 2020
- Resource page on HPTN 083 trial design and results, HPTN, July 2020
- HPTN 084 Primary Study Results Webinar, HPTN, November 2020
- HPTN 083 FINAL RESULTS: Pre-exposure Prophylaxis containing long-acting injectable cabotegravir is safe and highly effective for cisgender men and transgender women who have sex with men, presentation at AIDS 2020, July 8, 2020
Slide Decks
Putting the Research in Context
- A Conversation About Long-Acting PrEP for Cisgender Women, a conversation between Sinead Delany-Moretlwe, HPTN 084 Study Chair and Awelani Neluonde, CAB Member, AVAC’s Research Literacy Networking Zone at AIDS 2020, July 2020
- A Conversation About Long-Acting PrEP for MSM & Transgender Women, a conversation between Raphael Landovitz, HPTN 083 Study Chair and Jessica Salzwedel of AVAC, AVAC’s Research Literacy Networking Zone at AIDS 2020, July 2020
- Biomedical Prevention Implementation Collaborative (BioPIC) — Funded by the Bill & Melinda Gates Foundation as part of the AVAC and CHAI HIV Prevention Market Manager project, BioPIC is designed to close the gap between research and rollout for CAB-LA and future products
- Testing Long-Acting PrEP, Easier Said Than Done, Px Pulse podcast, October 2017 — Researcher and statistician Deborah Donnell describes the two different design approaches to the trials testing long-acting cabotegravir
- Px Wire: A Quarterly Update on HIV Prevention Research, April–June 2017, AVAC — This issue of Px Wire offers a guide to new types of trial designs, a summary of long-acting PrEP trials, a lexicon of key terms for the "post-placebo era", and a handy illustration for looking smart while you explain "double-dummy double-blind".